Zeltia Halts Irvalec Trials and Concentrates on Core Treatments

Spain’s Zeltia has announced that after a portfolio review, its PharmaMar unit has decided to end the development of one of their marine-based cancer drugs, Irvalec, and instead focus on advancing five drugs, including the already-approved Yondelis. Zeltia is a world-leading biopharmaceutical organisation, specialising in the development of marine based drugs for use in oncology

Continue Reading

Sanofi Announces Mixed News for Zaltrap

Sanofi and Regeneron have announced varied fortunes for their cancer drug Zaltrap, with the drug gaining a quick evaluation in the USA for colorectal cancer, but failing in a late-stage prostate cancer clinical trial. Sanofi announced today that the US Food and Drug Administration (FDA)  has granted priority review of the Biologics License Application for

Continue Reading

Novartis’ GIST Drug, Glivec, Receives European Commission Approval

Novartis announced earlier today that the European Commission has approved an update to their Glivec (imatinib) label to include 36 months of treatment after surgery, for adults with KIT (CD117)-positive gastrointestinal stromal tumours (GIST) who met the inclusion conditions of the pivotal study. The prolonged treatment has been demonstrated to increase recurrence-free survival and the

Continue Reading

Europe Approves AstraZeneca’s Caprelsa for Medullary Thyroid Cancer

AstraZeneca announced earlier today that the European Commission has granted marketing authorisation for their thyroid cancer pill, Caprelsa (vandetanib). The approval was given for the treatment of aggressive and symptomatic medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease.  The announcement comes three months after the European Medicines Agency’s Committee for

Continue Reading

Bayer To Submit Regorafenib After Positive Survival Statistics

Bayer has provided more information about their recently-halted late-stage trial of their colorectal cancer drug, regorafenib, which shows that the drug improved overall survival by 29%, meeting its primary endpoint. In October, the Phase III CORRECT (Colorectal cancer treated with regorafenib or placebo after failure of standard therapy) trial, which contained 760 patients with metastatic

Continue Reading

GSK’s Tykerb Fails to Meet Trial Targets

GlaxoSmithKline has suffered a setback from the news that Tykerb has failed a late-stage trial investigating whether adjuvant treatment with the drug improves disease-free survival in women with early-stage HER2 positive breast cancer. Results have been presented at the San Antonio Breast Cancer Symposium from TEACH (Tykerb Evaluation After Chemotherapy), a Phase III randomised, double-blind,

Continue Reading

Lantus Does Not Increase Cancer Risk, Claims Sanofi

Sanofi yesterday presented new data which they say supports the safety profile of their blockbuster drug, Lantus, hours after dismissing claims from a study that using the diabetes treatment more than doubled the risk of developing cancer. The French giant unveiled new meta-analysis data at the World Diabetes Congress in Dubai, which they say adds

Continue Reading

ASCO Report Argues Clinical Research Needs to Keep Up with Cancer Science

A new approach to therapy development, ‘smarter’, faster clinical trials and optimisation of health information technology are needed to deliver fully on the innovative advances in cancer seen in recent years, a new report claims. The report from the American Society of Clinical Oncology (ASCO), the world’s leading professional organization representing physicians who care for

Continue Reading